射血分数保留的心力衰竭的研究现状

doi:10.16753/j.cnki.1008-2344.2019.06.015

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1396 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要心力衰竭是一种全世界范围内的公共卫生问题。临床上，大约50%有心力衰竭症状和体征的患者的左室射血分数（LVEF）≥ 50%，通常称为射血分数保留的心力衰竭（HFpEF），是目前最普遍的心力衰竭形式。HFpEF具有高发病率、高死亡率的特点，容易被误诊或漏诊。本文从HFpEF的流行病学、发病机制、临床特征、生物标志物及治疗等方面进行了阐述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邰玉玲
	马晶茹

关键词 ：射血分数保留, 心力衰竭, 诊断

Abstract：Heart failure is a serious worldwide public health problem. Approximately 50% of patients with clinical features of chronic heart failure suffer from heart failure with reduced ejection fraction (HFpEF). HFpEF is characterized by classical heart failure symptoms with an ejection fraction equal to or greater than 50%, which is associated with high morbidity and mortality and easy to be misdiagnosed or missed diagnosis. This review summarizes the epidemiology, pathogenesis, clinical features, biomarkers and treatment of HFpEF.

Key words： preserved ejection fraction heart failure diagnosis

收稿日期: 2018-12-12

PACS:

R541.6

基金资助:辽宁省科学技术计划项目（No.2018225063）

通讯作者: 马晶茹(1970-),女(汉),主任医师,教授,硕士生导师,研究方向:冠心病的基础和临床研究及冠心病的介入治疗.E-mail:majingru1218@163.com E-mail: majingru1218@163.com

引用本文:

邰玉玲, 马晶茹. 射血分数保留的心力衰竭的研究现状[J]. 沈阳医学院学报, 2019, 21(6): 549-553. TAI Yuling, MA Jingru. Research progress of heart failure with preserved ejection fraction. Journal of Shenyang Medical College, 2019, 21(6): 549-553.

链接本文:

http://journal07.magtechjournal.com/syyxyxb/CN/10.16753/j.cnki.1008-2344.2019.06.015 或 http://journal07.magtechjournal.com/syyxyxb/CN/Y2019/V21/I6/549

[1]	Singh A, Mehta Y. Heart failure with preserved ejection fraction (HFpEF):Implications for the anesthesiologists[J]. J Anaesthesiol Clin Pharmacol, 2018, 34(2):161-165.
[2]	顾东风, 黄广勇, 何江, 等. 中国心力衰竭流行病学调查及其患病率[J]. 中华心血管病杂志, 2003, 31(1):3-6.
[3]	Benjamin EJ,Blaha MJ,Chiuve SE,et al. Heart disease and stroke statistics-2017 update:a report from the American Heart Association[J]. Circulation, 2017, 135(10):e146-e603.
[4]	Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival(from the Atherosclerosis Risk in Communities study)[J]. Am J Cardiol, 2008, 101(7):1016-1022.
[5]	葛均波, 徐永健, 王辰, 等. 内科学[M].9版. 北京:人民卫生出版社, 2018:164.
[6]	Yaku H,Ozasa N,Morimoto T, et al. Demographics, management, and in-hospital outcome of hospitalized acute heart failure syndrome patients in contemporary real clinical practice in Japan-observations from the prospective,multicenter Kyoto Congestive Heart Failure(KCHF)registry[J]. Circ J,2018, 82(11):2811-2819.
[7]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[8]	Del Buono MG, Buckley L, Abbate A. Primary and secondary diastolic dysfunction in heart failure with preserved ejection fraction[J]. Am J Cardiol, 2018, 122(9):1578-1587.
[9]	Shah SJ, Katz DH, Deo RC. Phenotypic spectrum of heart failure with preserved ejection fraction[J]. Heart Fail Clin, 2014, 10(3):407-418.
[10]	洪华山. 老年慢性心力衰竭的药物和非药物治疗现状[J]. 中华老年心脑血管病杂志, 2015, 17(8):785-788.
[11]	Yap J, Sim D, Lim CP, et al. Predictors of two-year mortality in Asian patients with heart failure and preserved ejection fraction[J]. Int J Cardiol,2015, 183:33-38.
[12]	Bhatia RS,Tu JV,Lee DS,et al. Outcome of heart failure with preserved ejection fraction in a population-based study[J]. N Engl J Med, 2006, 355(3):260-269.
[13]	Nair A, Deswal A. Aldosterone receptor blockade in heart failure with preserved ejection fraction[J]. Heart Fail Clin, 2018, 14(4):525-535.
[14]	苑晓烨, 华琦. 射血分数保留的心力衰竭研究现状[J]. 中华老年心脑血管病杂志, 2017, 19(8):881-883.
[15]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America[J]. J Am Coll Cardiol,2017, 70(6):776-803.
[16]	Li S, Zhang X, Dong M, et al. Effects of spironolactone in heart failure with preserved ejection fraction:A meta-analysis of randomized controlled trials[J]. Medicine (Baltimore), 2018, 97(35):e11942.
[17]	喻江标, 吴永港, 张银妆, 等. ACE2-Ang(1-7)-Mas受体轴在高血压射血分数保留心力衰竭中的作用[J]. 中南大学学报(医学版), 2018, 43(7):738-746.
[18]	Levine AR, Simon MA, Gladwin MT. Pulmonary vascular disease in the setting of heart failure with preserved ejection fraction[J]. Trends Cardiovasc Med, 2019, 29(4):207-217.
[19]	张湘, 张学铭, 王赛华, 等. 法舒地尔治疗老年左心室射血分数保留的心力衰竭相关性肺动脉高压的研究[J]. 临床内科杂志, 2017, 34(12):837-840.
[20]	Lee MS, Duan L, Clare R, et al. Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction[J]. Am J Cardiol, 2018, 122(3):405-412.
[21]	Ferrari R, Böhm M, Cleland JG,et al. Heart failure with preserved ejection fraction:uncertainties and dilemmas[J]. Eur J Heart Fail,2015, 17(7):665-671.
[22]	Lopes CP, Danzmann LC, Moraes RS, et al. Yoga and breathing technique training in patients with heart failure and preserved ejection fraction:study protocol for a randomized clinical trial[J]. Trials, 2018, 19(1):405.
[23]	Bowen TS, Brauer D, Rolim NPL, et al. Exercise training reveals inflexibility of the diaphragm in an animal model of patients with obesity-driven heart failure with a preserved ejection fraction[J]. J Am Heart Assoc, 2017, 6(10):e006416.
[24]	Kaye DM, Petrie MC, McKenzie S, et al. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction[J]. ESC Heart Fail, 2019, 6(1):62-69.
[25]	孔祥清, 孙伟."中国研发"治疗心衰[J]. 祝您健康, 2019(3):18.
[26]	Mishra M, Muthuramu I, Aboumsallem JP, et al. Reconstituted HDL(Milano)treatment efficaciously reverses heart failure with preserved ejection fraction in mice[J]. Int J Mol Sci, 2018, 19(11):E3399.
[27]	Senni M,Paulus WJ,Gavazzi A,et al. New strategies for heart failure with preserved ejection fraction:the importance of targeted therapies for heart failure phenotypes[J]. Eur Heart J, 2014, 35(40):2797-2815.